Interim Data Demonstrating Safety & Confirmed Clinical Responses of ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Ph 1b/2 Trial Announced
“The emerging data from our combination trials for ADG126 SAFEbody meet our target product profile in clinic and highlight the massive potential of a best-in-class anti-CTLA-4 therapy,” said Peter Luo, Ph.D., Co-founder and CEO of Adagene. “We look forward to advancing this program in 2023 via both Adagene and Roche sponsored studies in areas of unmet medical needs in oncology. We plan to present the detailed results from these dose escalation cohorts and report the phase 2 proof-of-concept data from our dose expansion cohorts in target indications in 2023.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo